Patterson Companies (PDCO) recently announced that it has entered into a definitive agreement to be acquired by Patient Square Capital (Patient Square), a dedicated healthcare investment firm.Patterson’s shareholders will receive $31.35 in cash per share per the acquisition agreement with Patient Square, indicating a 49% premium over its 30-day volume-weighted average price as of Dec. 4, 2024. The total transaction is valued at approximately $4.1 billion, including the refinancing of Patterson’s receivables ...

December 11th was a very interesting day for shareholders of Patterson Companies (NASDAQ: PDCO ). Shares of the company skyrocketed, closing up 35.9%, after news broke that management had agreed to sell off the business wayCrude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth cash flow analy ...

核心观点 - Monteverde & Associates PC 正在调查 Patterson Companies, Inc. 与 Patient Square Capital 的拟议合并，股东将获得每股 31.35 美元的现金[1] 公司信息 - Monteverde & Associates PC 是一家位于纽约帝国大厦的律师事务所，被 ISS Securities Class Action Services Report 评为前 50 名公司，已为股东追回数百万美元[1] - 公司提供免费咨询，无费用或义务[2] - 公司在全国范围内处理证券集体诉讼，并在各级法院，包括美国最高法院，有成功的记录[3] 合并信息 - Patterson Companies, Inc. 的股东将根据合并协议获得每股 31.35 美元的现金[1] 联系方式 - 公司地址：The Empire State Building, 350 Fifth Ave. Suite 4740, New York, NY 10118, United States of America[4] - 联系人：Juan Monteverde, Esq.，电话：(212) 971-1341，邮箱：[email protected][4]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ FORM 10-Q ____________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED October 26, 2024. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-20572 ______________________________ ...

Patterson Cos. (PDCO) came out with quarterly earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.08%. A quarter ago, it was expected that this medical supplies maker would post earnings of $0.32 per share when it actually produced earnings of $0.24, delivering a surprise of -25%.Over the last four quarters, ...

销售额 - 第二季度净销售额同比增长1.3%至16.7亿美元，内部销售额增长0.6%[2] - 第二季度动物健康部门净销售额为10.5亿美元，内部销售额增长1.9%[10] - 第二季度牙科部门内部销售额下降2.3%，其中设备销售额下降7.5%，增值服务销售额下降2.7%[8] - 公司2024年第三季度净销售额为16.74亿美元，相比2023年同期的16.53亿美元略有增长[36] - 公司总销售额为1,674,375千美元，同比增长1.3%[42] - 动物健康部门销售额为1,054,588千美元，同比增长2.9%[42] - 牙科部门销售额为611,682千美元，同比下降2.3%[42] - 公司六个月总销售额为3,216,117千美元，同比下降0.4%[44] - 动物健康部门六个月销售额为2,037,001千美元，同比增长0.1%[44] - 牙科部门六个月销售额为1,162,039千美元，同比下降2.7%[44] - 2023年10月28日止三个月的净销售额为16.53亿美元，非GAAP净销售额为16.56亿美元[49] - 2024年10月26日止六个月的净销售额为32.16亿美元，非GAAP净销售额为32.12亿美元[51] - 2023年10月28日止六个月的净销售额为32.30亿美元，非GAAP净销售额为32.39亿美元[51] 收益与利润 - 第二季度GAAP每股收益为0.30美元，调整后每股收益为0.47美元，均受网络安全攻击影响[3] - 公司修订2025财年GAAP每股收益指引为1.83至1.93美元，调整后每股收益指引为2.25至2.35美元[15] - 2024年第三季度毛利润为3.28亿美元，相比2023年同期的3.39亿美元有所下降[36] - 2024年第三季度营业费用为2.90亿美元，相比2023年同期的2.82亿美元有所增加[36] - 2024年第三季度营业利润为3763.6万美元，相比2023年同期的5690.3万美元大幅下降[36] - 2024年第三季度净利润为2669.6万美元，相比2023年同期的3985.5万美元有所下降[36] - 2024年第三季度每股基本收益为0.30美元，相比2023年同期的0.42美元有所下降[36] - 公司第三季度运营收入为37,636千美元，同比下降33.9%[46] - 动物健康部门第三季度运营收入为29,621千美元，同比增长12.4%[46] - 牙科部门第三季度运营收入为33,660千美元，同比下降39.1%[46] - 公司第三季度净利润为26,769千美元，同比下降36.0%[47] - 2023年10月28日止三个月的净收入为3995.8万美元，非GAAP净收入为4728.1万美元[49] - 2023年10月28日止三个月的毛利率为20.5%，非GAAP毛利率为20.6%[49] - 2024年10月26日止六个月的净收入为4048.4万美元，非GAAP净收入为6287.7万美元[51] - 2024年10月26日止六个月的毛利率为19.9%，非GAAP毛利率为20.0%[51] - 2023年10月28日止六个月的净收入为7119.2万美元，非GAAP净收入为8583.7万美元[51] 现金流与财务状况 - 第一季度至第二季度，公司通过现金股息和股票回购向股东返还9620万美元[3] - 第一季度至第二季度，公司自由现金流改善4150万美元[11] - 截至2024年10月26日，公司现金及现金等价物为1.58亿美元，相比2024年4月27日的1.14亿美元有所增加[38] - 2024年上半年经营活动产生的净现金为-4.59亿美元，相比2023年同期的-4.85亿美元有所改善[40] - 2024年上半年投资活动产生的净现金为5.49亿美元，相比2023年同期的4.55亿美元有所增加[40] - 2024年上半年融资活动产生的净现金为-4886.9万美元，相比2023年同期的-1318.1万美元有所减少[40] - 2024年10月26日止六个月的自由现金流为1215.9万美元，2023年同期为-2929.1万美元[53] 战略与股东价值 - 公司宣布评估战略替代方案以最大化股东价值[3] - 公司正在评估潜在战略替代方案，包括出售、合并、战略业务组合或其他交易[18]

Wall Street analysts expect Patterson Cos. (PDCO) to post quarterly earnings of $0.49 per share in its upcoming report, which indicates a year-over-year decline of 2%. Revenues are expected to be $1.64 billion, down 0.7% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company announces its earnings, it is ess ...

Patterson Companies, Inc. (PDCO) is set to release second-quarter fiscal 2025 results on Aug. 28, before the opening bell.The company missed on earnings in the last reported quarter. Its earnings missed the Zacks Consensus Estimate in three of the trailing four quarters and met in one, delivering a negative average surprise of 4.53%.Q2 EstimatesThe Zacks Consensus Estimate for the company’s revenues is pegged at $1.64 billion, down 0.7% year over year.The consensus mark for adjusted earnings per share is pi ...

Patterson Companies, Inc.'s (PDCO) subsidiary, Patterson Dental Supply, Inc., recently announced an agreement in principle between Patterson and PDS Health to extend their relationship through the end of 2027. The extension is expected to allow Patterson Companies to continue as the premier distributor for all merchandise, services, technology and core equipment across PDS Health’s network of more than 1,000 supported practices nationwide.PDS Health, earlier known as Pacific Dental Services, is a renowned d ...

Patterson Companies (PDCO) recently announced that it has signed two separate acquisition agreements for its Animal Health business, Infusion Concepts in the United Kingdom and Mountain Vet Supply in the United States. These acquisition agreements are likely to further strengthen PDCO's Animal Health business. Terms of the transaction are not yet disclosed. Patterson Companies expects to close the transactions during the second quarter of fiscal 2025. Likely Trend of PDCO Stock Following the News Following ...